论文部分内容阅读
目的:探讨产前加强监护对妊娠期合并血小板减少性紫癜(ITP)患者母婴妊娠结局的影响。方法:选取该院2010年1月～2013年1月实施产前监护的妊娠期ITP患者32例为观察组,并与2006年1月～2009年12月进行常规产前监护的妊娠期ITP患者30例(对照组)进行对比分析,观察两组产妇转归情况、妊娠合并症发生情况、剖宫产率、胎儿出生情况等方面的差异。结果:观察组监护后血小板计数高于对照组,而产中出血量、产后出血量显著低于对照组,差异有统计学意义(P<0.05)。对照组患者并发症发生率为15.63%,剖宫产率为50.00%,对照组的并发症发生率是43.33%,剖宫产率为76.67%,两组并发症发生率及剖宫产率具有统计学差异(P<0.05),而两组死亡率无统计学差异(P>0.05)。观察组新生儿Apgar评分为(9.3±1.2)分优于对照组(7.9±1.1)分,差异有统计学意义(P<0.05)。结论:对妊娠合并ITP产妇加强妊娠期监护可有效降低产妇并发症发生率,减少产妇分娩出血量,有利于提高患者血小板水平,有利于母婴预后。
Objective: To investigate the effect of prenatal intensive care on pregnant women with pregnancy-induced thrombocytopenic purpura (ITP). Methods: Thirty-two ITP patients during prenatal care from January 2010 to January 2013 in our hospital were enrolled in this study. Patients with ITP during pregnancy were enrolled in this study. The patients underwent prenatal care from January 2006 to December 2009 30 cases (control group) were compared and analyzed to observe the two groups maternal outcome, pregnancy complications, cesarean section rate, fetal birth and so on. Results: The platelet count of the observation group was higher than that of the control group, while the amount of bleeding in the middle part and the amount of postpartum hemorrhage in the observation group were significantly lower than those in the control group (P <0.05). The incidence of complications in the control group was 15.63%, the rate of cesarean section was 50.00%, the incidence of complications in the control group was 43.33%, the rate of cesarean section was 76.67%, the incidence of complications and cesarean section rate (P <0.05), but there was no significant difference between the two groups (P> 0.05). The neonatal Apgar score of the observation group was (9.3 ± 1.2) points better than that of the control group (7.9 ± 1.1) points, the difference was statistically significant (P <0.05). Conclusion: Pregnancy with ITP maternal enhancement of pregnancy monitoring can effectively reduce the incidence of maternal complications and reduce the amount of maternal bleeding, help to improve the level of patients with platelets, maternal and child prognosis.